Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Laura BraconiSection of Pharmaceutical and Nutraceutical Sciences, Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.ORCID 0000-0002-0861-0706
Chiara RigantiOncological Pharmacology Laboratory and Molecular Biotechnology Center "Guido Tarone", Department of Oncology, University of Turin, Piazza Nizza 44, 10126 Torino, Italy.ORCID 0000-0001-9787-4836
Astrid ParentiSection of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Viale Pieraccini 6, 50139 Firenze, Italy.ORCID 0000-0002-7980-6853
Marta CecchiSection of Pharmacology and Toxicology, Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Viale Pieraccini 6, 50139 Firenze, Italy.ORCID 0000-0002-8777-6674
Alessio NocentiniSection of Pharmaceutical and Nutraceutical Sciences, Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.ORCID 0000-0003-3342-702X
Gianluca BartolucciSection of Pharmaceutical and Nutraceutical Sciences, Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.ORCID 0000-0002-5631-8769
Marta MenicattiSection of Pharmaceutical and Nutraceutical Sciences, Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.
Marialessandra ContinoDepartment of Pharmacy-Drug Sciences, University of Bari "A. Moro", via Orabona 4, 70125 Bari, Italy.ORCID 0000-0002-0713-3151
Nicola Antonio ColabufoDepartment of Pharmacy-Drug Sciences, University of Bari "A. Moro", via Orabona 4, 70125 Bari, Italy.
Dina ManettiSection of Pharmaceutical and Nutraceutical Sciences, Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.ORCID 0000-0002-5881-6550
Maria Novella RomanelliSection of Pharmaceutical and Nutraceutical Sciences, Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.ORCID 0000-0002-5685-3403
Claudiu T SupuranSection of Pharmaceutical and Nutraceutical Sciences, Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.ORCID 0000-0003-4262-0323
Elisabetta TeodoriSection of Pharmaceutical and Nutraceutical Sciences, Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.ORCID 0000-0002-9705-3875
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
A new series of piperazine derivatives were synthesized and studied with the aim of obtaining dual inhibitors of P-glycoprotein (P-gp) and carbonic anhydrase XII (hCA XII) to synergistically overcome the P-gp-mediated multidrug resistance (MDR) in cancer cells expressing the two proteins, P-gp and hCA XII. Indeed, these hybrid compounds contain both P-gp and hCA XII binding groups on the two nitrogen atoms of the heterocyclic ring. All compounds showed good inhibitory activity on each protein (P-gp and hCA XII) studied individually, and many of them showed a synergistic effect in the resistant HT29/DOX and A549/DOX cell lines which overexpress both the target proteins. In particular, compound
Indexed as
ATP Binding Cassette Transporter, Subfamily B, Member 1Carbonic Anhydrase InhibitorsCarbonic AnhydrasesDrug Resistance, MultipleDrug Resistance, NeoplasmPiperazinesA549 CellsAntineoplastic AgentsCell Line, TumorDoxorubicinHT29 CellsHumansMolecular StructurePiperazineStructure-Activity RelationshipAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Carbonic Anhydrase InhibitorsCarbonic Anhydrasescarbonic anhydrase XIIDoxorubicinPiperazinePiperazinesA549/DOXCA XII inhibitorsdual P-gp/CA XII inhibitory activityHT29/DOXhybrid compoundsK562/DOXMDR reversersmultitarget ligandsP-gp modulatorsselective chemosensitizers
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Dual Inhibitors of P-gp and Carbonic Anhydrase XII (hCA XII) against Tumor Multidrug Resistance with Piperazine Scaffold. · full record | Socratic